EPL reported strong Q1 results with revenue up 25.3% (underlying 20% growth) and EBITDA up 15.2% (underlying margin 19.6%). PBT rose 10%, with full-year double-digit PAT growth expected.

Growth was broad-based across Beauty & Cosmetics and Oral Care.

Outlook raised to high-teens revenue growth for upcoming quarters, maintaining ~20% underlying EBITDA margin.

The Indovida merger, approved by CCI, is progressing; Indovida posted Q1 EBITDA of ₹383 Cr.

Management is confident in cost recovery through pricing and leveraging strategic investments to drive profitable growth and expand beyond tubes.